MKI67 and cancer: The pronounced suppression of xenograft growth by USP22 knockout was further supported by immunostaining of Ki67 (a proliferation marker), which showed that the intensity of Ki67 immunostaining and percentage of Ki67-positive cells were much lower in USP22−/− cancer cell xenografts than their parent cancer cells (Fig. 3d, upper panel).